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Introduction
Central Nervous System (CNS) infections are still an
important cause of morbidity and mortality despite
newly developed vaccines and continuous improve-
ment in health care. There are more than a dozen
species of viruses, bacteria, fungi and parasites capable
of causing meningitis or encephalitis. However, dis-
ruption of the blood-brain barrier (BBB) and leukocyte
infiltration of the CNS are hallmarks of meningitis,
regardless of the causative agent. This transmigration
of leukocytes into the brain parenchyma occurs via a
multi-step process that is mediated by a number of
adhesion molecules, selectins and enzymes.
Matrix metalloproteinases (MMPs) are peptides
that play an important role in brain injury during infec-
tious and noninfectious inflammation of the central
nervous system. This growing family of endopeptidas-
es is capable of degrading components of the extracel-
lular matrix (ECM). In addition to its structural func-
tions, the ECM also serves as a reservoir of substances
that modulate cell proliferation, differentiation, migra-
tion and death. MMPs have been implicated in several
diseases of the central nervous system. For example,
increased expression of MMPs has been observed in
multiple sclerosis [1], experimental autoimmune
encephalomyelitis [2], Alzheimer's disease [3], stroke
[4] and meningitis [5]. Numerous studies have provid-
ed converging evidence that MMPs play a key role in
the pathogenesis of meningitis through their contribu-
tion to the breakdown of the BBB and the accumula-
tion of blood-derived immune cells. Gelatinases
(MMP-2 and MMP-9) are probably the most exten-
sively studied MMPs in the context of the pathogene-
sis of meningitis [6-8]. However, the cellular sources
of MMP activity in the CNS are not yet clear. It has
been suggested that resident cells of the brain, includ-
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ing neurons, astrocytes, microglia and endothelial
cells, contribute to the increased expression of MMPs
in the CNS during meningitis. It has also been sug-
gested that inflammatory infiltrates such as mono-
cytes, macrophages and granulocytes could possible
contribute to this increased expression.
Although it is well known that metalloproteinases
are mediators of disease, they also have beneficial
functions during the development of CNS and repair
following injury [9]. Accordingly, inhibition of metal-
loproteinase activity leads to alleviation of neuroin-
flammation. The activity of MMPs is regulated on sev-
eral levels, including gene transctiption, pro-enzyme
activation and inhibition by non-specific or specific
enzyme inhibitors. Tissue inhibitors of metallopro-
teinases (TIMPs) are specific endogenous inhibitors of
matrix metalloproteinases that form 1:1 enzyme-
inhibitor complexes. Currently, there are four known
TIMPs, each of which differs in its affinity for specif-
ic metalloproteinases. The balance between MMPs
and TIMPs regulates extracellular matrix remodeling
during the pathogenesis of disease. Furthermore,
TIMPs are not only protease inhibitors, but also appear
to be important signal transducers [10]. Finally, it is
believed that astrocytes produce the majority of TIMPs
in the central nervous system. 
In the present study, we examined the immunoreac-
tivity of gelatinases (MMP-2 and MMP-9) and two
TIMPs (TIMP-1 and TIMP-2) in autopsy brain tissue
obtained from patients who were afflicted with puru-
lent and lymphocytic viral CNS infections. We also
attempted to determine potential cellular sources of
their activity in the central nervous system.
Materials and methods
Tissue samples. Autopsy brain tissue samples (postmortem delay
range 12-16 hours) taken from cortex and subsubcortical white
matter from five patients diagnosed with lymphocytic viral menin-
gitis (aged 48-68 years), five patients diagnosed with purulent
meningoencephalitis (aged 42-71 years) and five patients without
any known abnormalities of the CNS (aged 40-73 years; cause of
death: myocardial infarction-3, pneumonia-2) were evaluated in
this study. The ratio of male to female was 2:3 in all investigated
groups. All of the clinical diagnoses of CNS infection were con-
firmed by histopathological microscopic examination. This study
protocol was approved by Ethics Committee of the University. 
Immunohistochemistry. Paraffin-embedded sections with a width
of 5 µm were mounted on glass slides and then deparaffinized with
xylene and a series of ethanol. The sections were then treated with
0.5% hydrogen peroxide in methanol for 10 minutes to block the
endogenous peroxidase activity, after which they were washed in
tap water. A high temperature antigen unmasking technique was
then applied to all sections. Next, the sections were placed in nor-
mal serum for 10 minutes and then incubated for 60 minutes with
primary antibodies (mouse monoclonal anybodies, Novocastra,
UK) specific to MMP-2 (dilution 1:40), MMP-9 (dilution 1:40),
TIMP-1 (dilution 1:75) or TIMP-2 (dilution 1:40). For negative
controls, the primary antibodies were omitted. 
The avidin-biotin technique was then employed to stain the sam-
ples. In this technique, a biotinylated secondary antibody reacts with
several peroxidase-conjugated streptavidin molecules (Dako
Cytomation LSAB+ System). Briefly, the sections were rinsed in
TBS buffer, after which they were incubated with biotinylated link
antibody and peroxidase-labeled streptavidin. The immunoreactivity
was then visualized by incubating the samples in 3,3’-diaminobenze-
dine. Finally, the slides were counterstained with hematoxilin. 
All sections were then evaluated by an experienced patholo-
gist. Immunoreactivity was assessed using a semi-quantitative
score, with 0 indicating that the sample was not immunoreactive
and 1, 2 and 3 indicating weak, moderate and intense immunore-
activity, respectively.
Results
To identify potential cellular sources of MMP and
TIMP activity in the CNS, we performed an in-depth
analysis of their immunoreativity in CNS endothelial
cells, astrocytes, neurons and inflammatory infiltrates
throughout brain parenchyma obtained from meningi-
tis patients and then compared the results to those
obtained when control samples were analyzed (Fig. 1).
In addition, infiltrating mononuclear or polymor-
phonuclear cells were also assessed to determine if
MMP or TIMP positive signals occurred in thickened
meninges during meningitis (Fig. 2).
MMP-9 was immunolocalized in the endothelial
cells from normal controls (Fig. 3a); however, the
expression increased in cells obtained from patients that
had meningitis of a viral origin (Fig. 3b). This increase
in expression was even more apparent in samples
obtained from patients with bacterial meningitis. Con-
versely, MMP-9 immunoreactivity decreased in astro-
cytes obtained from patients who had viral and bacteri-
al meningitis when compared to controls, whereas
TIMP-1 expression increased upon meningitis (Fig. 3c,
d). No distinct changes in MMP-2 immunoreactivity
(Fig. 3e) were observed in response to meningitis in any
of the cell types evaluated in this study.
Interestingly, the neurons were consistently found
to be positive for gelatinases and TIMPs in the control
group and both meningitis groups. This finding indi-
cates that this type of cell may be an important source
of MMP and TIMP activity in both healthy individuals
and in individuals with meningitis (Fig. 3f, g). 
Image analysis revealed strong MMP-9, TIMP-1
and TIMP-2 positive signals in leukocyte infiltrates
along the thickened meninges in samples obtained
from patients with viral and bacterial meningitis. Fur-
thermore, MMP-9 (Fig. 3h) and TIMPs immunoreac-
tivity appeared to be greater in samples from patients
that were afflicted with bacterial infection than in sam-
ples from patients who had viral meningitis.
Discussion
This study examined the immunoreactivity of matrix
metalloproteinases (MMP-9 and MMP-2) and their tis-
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sue inhibitors (TIPM-1 and TIMP-2) in autopsy brain tis-
sues obtained from patients with infectious inflammation
to identify potential sources of their activity in the CNS.
The results of this study revealed that MMP-2 was
immunolocalized in both normal controls and menin-
gitis samples in brain parenchyma. Control samples
and meningitis samples showed the same level of
MMP-2 expression. In cantrast, MMP-9 immunoreac-
tivity in brain endothelial cells, a key component of the
blood-brain barrier, was higher in samples collected
from patients with meningitis than in samples collect-
ed from control patients. These findings suggest that
MMP-9 is crucially involved in the pathogenesis of
meningitis, but that MMP-2 may not be, which is in
accordance with the results of other studies. For exam-
ple, in cases of tuberculous meningoencephalitis,
MMP-9 was visualized in inflammatory infiltrates in
the brain parenchyma, but MMP-2 was not, even
though they were both present in infiltrating mononu-
clear cells [11]. In that study, MMP-2 was also detect-
ed in every cerebrospinal fluid (CSF) sample evaluat-
ed while MMP-9 was only detected in samples col-
lected from patients with inflammatory diseases when
measured using an enzyme immunoassay. Further-
more, in a study that evaluated children with bacterial
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Fig. 1. Expression of MMP-2, MMP-9, TIMP-1 and TIMP-2 in
endothelial cells, astrocytes and inflammatory infiltrates in sam-
ples collected from normal controls (C), as well as samples col-
lected from patients with viral (V) and bacterial (B) meningitis. 0,
no immunoreactivity, 1, weak immunoreactivity, 2, moderate
immunoreactivity, 3, intense immunoreactivity. Lines represent
the mean value.
Fig. 2. Thickened meninges. Immunodetection of MMP-2, MMP-
9, TIMP-1 and TIMP-2 in infiltrating mononuclear cells in sam-
ples collected from patients with viral meningitis and polymor-
phonuclear cells in samples collected from patients with bacterial
meningitis. Lines represent the mean value.
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Fig. 3. Matrix metalloproteinase-9 (MMP-9) staining: endothelial layer in normal controls (a) and increased expression in samples
obtained from patients with viral meningitis (b). Tissue inhibitor of metalloproteinase-1 (TIMP-1): increased expression was observed in
astrocytes from meningitis patients (c) when compared to those from normal controls (d). MMP-2 immunolocalized in endothelial cells
from viral meningitis (e). MMP-2 (f) and TIMP-2 (g) positive neurons. Strong MMP-9 immunoreactivity in polymorphomuclear cells (h)
in purulent meningoencephalitis (magnification ×400).
meningitis, both gelatinases were detected in the CSF,
while only MMP-2 was observed in CSF samples col-
lected from controls [12]. However, detectable MMP-
9 levels have been found in CSF samples from some
patients with viral meningitis when they were not pres-
ent in samples collected from controls, and these lev-
els were found to be correlated with CSF pleocytosis.
In addition, in cases of viral meningitis, MMP-2 has
been shown to be constantly expressed, but not upreg-
ulated [13]. Direct interaction with an etiological agent
during meningitis could explain this increased MMP
activity. Indeed, treatment with heat-inactivated Strep-
tococcus pneumoniae was found to stimulate the
release of MMP in brain endothelial cells [14]. Taken
together, the results of the present study and previous
findings demonstrate that MMP-9 plays a key role in
CNS inflammation.
In this study, immunohistochemistry revealed that
the expression pattern of the evaluated MMPs and
TIPMs varied depending on cell type. Astrocytes
appear to be crucially involved in the overall regula-
tion of MMP activity. Interestingly, we found a
decrease in MMP-9 immunoreactivity in astrocytes in
samples collected from patients with meningitis and
increase in TIMP-1 immunoreactivity under the same
conditions. These findings may indicate that MMP-
TIMP complexes form during inflammation. Astro-
cytes are an important source of TIMP activity [15,
16], and a net balance between MMPs and TIMPs may
be involved in the pathogenesis of CNS disease [17].
In addition to inhibiting MMPs, TIMPs are multi-
functional molecules that have distinct biological
roles [18]. Furthermore, like MMPs, TIMPs induce
both beneficial and detrimental effects [19].
Analysis from serial lumbar punctures [7]
revealed that the concentration of MMPs in the cere-
brospinal fluid are only partially correlated with the
CSF leukocyte count. This suggests that invading
immune cells are only partially responsible for the
activity of MMPs in the CSF during meningitis;
therefore, parenchymal cells may be another relevant
source. In this study, we found neurons to be a stable
source of MMPs and TIPMs in the CNS in meningi-
tis patients and normal controls. 
The results of this study revealed that MMP-9 and
TIMP-1 was much more immunoreactive in inflam-
matory infiltrates of meninges from patients afflicted
with bacterial meningitis when compared to patients
afflicted with viral meningitis. In a study of patients
with tuberculosis meningitis, both MMP-2 and
MMP-9 were immunolocalized to infiltrating
mononuclear cells in the meninges but TIMP-1 and
TIMP-2 were expressed in only a small number of
inflammatory cells in thickened meninges [11]. How-
ever, positive signals for MMP-9 and TIPM-1 were
shown to be localized in infiltrating polymorphonu-
clear cells and mononuclear cells in mice that had
eosinophilic meningitis [20].
Understanding the processes that lead to brain
damage during meningitis is crucial for the develop-
ment of future drugs and the improvement of treat-
ment protocols. Previous studies have generated
encouraging data regarding the modulation of MMPs
during CNS repair following injury. For example,
inhibition of MMPs in rats was shown to prevent
kainic acid-induced cell death in the brain, which
suggests that MMP inhibitors have some therapeutic
potential [21]. Furthermore, inhibition of MMPs
using a broad-spectrum metalloproteinase inhibitor
ameliorated neutrophil infiltration following intrac-
erebral haemorrhage and induced function improve-
ment and a decrease in the volume of injury [22]. It is
likely that regulating MMP activity could enable ben-
eficial effects in the treatment of neuroinflammation
as well; however, further investigation focused on spe-
cific target cells in the central nervous system is
required.
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